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Primary Immunodeficiencies (PIDs) compose of a large spectrum of diseases 
characterized by abrogated or dysregulated functions of innate and adaptive 
immune system components that cause susceptibility to recurrent infections, auto-
immunity, neoplasia/malignancy and dysfunction of organs and skeletal system. 
PIDs are also evaluated as molecular diseases due to the mutations in one or more 
genes. That affects transcripts and protein expressions as well as their functions. 
Today, 430 different genes are known to have various functional effects which are 
related to 403 different PIDs. Analyzing the effects of the mutations on relevant 
protein expression and function is significant to diagnose and the follow-up of the 
PIDs. Application of flow cytometry for analyzing protein expression levels and 
functions in immune cells as well as investigating the cellular functions tender 
a rapid, quantitative and reliable approach to identify and to prove the genetic 
background of PIDs. Therefore, the use of flow cytometry aids to have a large 
spectrum of data from gene to function and from function to clinical relevance in 
the first-step and differantial diagnosis of PIDs.
Keywords: Primary immunodeficiency, flow cytometry, molecular diagnosis, 
immunophenotyping, PBMC culture, functional assays, intracellular staining,  
PI3K pathway analysis- flow, CFSE cell proliferation
1. Introduction
Primary immunodeficiencies (PIDs) are rare and heterogenous genetic dis-
eases of the immune system. According to updated IUIS (International Union of 
Immunological Societies) classification in 2019, there is a large spectrum of PIDs 
including 403 different diseases caused by mutations in 430 genes categorized 
10 different subclasses with these topics: Severe combined immunodeficiencies 
(SCIDs), combined immunodeficiencies (CIDs) less profound than SCID, CIDs 
with associated or syndromic features and predominantly antibody deficiencies 
including common variable immunodeficiency (CVID), immune dysregulation, 
phagocyte system defects, innate immune defects, auto-inflammation, complement 
deficiencies, bone marrow abnormalities and phenocopies of PIDs. Each disease has 
unique laboratory and clinical manifestations. Decreased or increased immune cell 
counts, unbalanced immune cell plasticity, decreased or increased immunoglobulin 
levels and complement factors, dysregulated functions of immune cells due to 
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abrogated intracellular molecular functions cause developing clinical manifesta-
tions of PIDs [1]. Use of flow cytometry in these laboratory investigations is a 
significant approach that offers a quantitative, reliable and rapid results. Evaluation 
of these laboratory findings helps to clinicians for proper diagnose of PIDs [2, 3].
2. Analysis of inflammatory and regulatory cell profiles in PIDs
Immune dysregulation with autoimmunity is observed in many PIDs such 
as LRBA, CTLA4, STAT3 GOF, PIK3CD deficiencies as well as IPEX syndrome 
caused by loss or dysfunctional FOXP3 expression [4–18]. Disrupted T helper 
cell plasticity is pointed out as a prominent feature of the autoimmunity in PIDs. 
Deregulated numbers and functions of Treg cells are observed in most of the 
patients with IPEX or IPEX-like (such as in patients with LRBA deficiency) [6, 7, 
19–21]. Decreased Treg cell numbers or loss of Treg cell functions are related to 
severe form of autoimmunities in PIDs. In contrast, deregulated inflammatory 
cell numbers/ratios and the inflammatory cytokines produced by inflamma-
tory cells are observed as autoimmune manifestations of PIDs such as LRBA and 
STAT3 LOF deficiencies. In LRBA deficiency, increased number of circulating 
T folicular helper (Tfh) is associated with autoimmune manifestations of the 
disease [5]. Moreover, decreased Th17 cell numbers are related to inflammatory 
response to Candida infections observed in patients with LOF mutations in STAT3 
deficiency [22–24].
In these cases, the first attempt is to analyze regulatory and inflammatory cell 
ratios in the clinical immunology laboratory to clarify the cellular background of 
autoimmunity.
2.1 Analysis of Treg cells in PIDs
Treg cells are unique subset of T helper cells through its equilibrating functions 
on immune response to self and foreign antigens. Tregs suppress inflammatory T 
cell function and proliferation, therefore it plays critical roles to prevent autoim-
mune disorders. In PIDs with autoimmunity, impaired functions of Treg cells in 
parallel with decreased number of Treg cells are observed. IPEX is a well-known 
syndrome affecting Treg cell development due to mutations of FOXP3 which 
is a main transcription factor in the development of Treg cells. In patients with 
IPEX syndrome, loss of circulating and tissue associated Treg cells are thought to 
cause the multi-organ autoimmune manifestations [6, 20, 21]. Patients with CD25 
(IL-2Rα) deficiency have IPEX-like phenotype as well as in patients with LRBA 
deficiency. Decreased Treg ratio is a significant laboratory characteristics in these 
PIDs [7, 25]. In patients with AIRE deficiency which is related to Autoimmune Poly 
Endocrinopathy, Candidiasis and Ectodermal Dystrophy (APECED) syndrome, 
decreased Treg cell ratio and function are associated with the occurrence of the 
disease [26].
Investigating Treg cell ratio by flow cytometry provides an important insight to 
understand autoimmunity from the benchside to bedside.
Below, it was described the Treg staining protocol and the gating strategy for 
human peripheral blood Treg cells (Figure 1).
2.1.1 Treg staining protocol
• Peripheral blood mononuclear cells (PBMCs) are separated by ficoll density 
gradient protocol from 4 ml of whole blood in tube with EDTA.
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• Wash PBMCs with Phosphate Buffer Saline (PBS) buffer, centrifuge at 300 g 
for 5 min and discard the supernatant
• Add appropriate volume of PBS and add 100 ul cell to flow cytometer  
tubes
• Add appropriate volume of CD4, CD127 and CD25 antibodies and incubate at 
room temperature and dark conditions for 20 min
• Following incubation wash with PBS, centrifuge at 500 g for 5 min and discard 
the supernatant
• Fix the cells with a fixation buffer for 10–20 min
• Wash with PBS, centrifuge at 500 g for 5 min and discard the supernatant
• Treat with the permeabilization buffer for 10–30 min
• Wash with PBS, centrifuge at 500 g for 5 min and discard the supernatant
• Add FOXP3 antibody for 30 min at room temperature and dark conditions
• Wash with PBS, centrifuge at 500 g for 5 min and discard the supernatant
• Add 300 ul PBS, vortex and analyze in flow cytometer
2.2 Analysis of circulating Tfh and TH17 cells in PIDs
Tfh cells are specialized Th cell subset which plays important role in B cell 
differentiation in lymph nodes, in producing high affinity antibodies and the 
Figure 1. 
Representative image of CD4+ CD127loCD25hi FOXP3+ Treg cells in peripheral blood of healthy control and a 
patient.
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development of memory cells. Therefore, Tfh provides help germinal center 
(GC) formation and selection of plasma cells [27–30]. Tfh cells have unique 
molecules that are expressed in cell surface and have special functions such as 
CXCR5. CXCR5 is a chemokine receptor and provides migration of Tfh cells to 
GC zone. Besides, Tfh expresses B Cell Lymphoma (BCL-6) and (Inducible T Cell 
Costimulator) ICOS or CD278 on their surfaces. Increased Tfh cell numbers in 
peripheral blood are investigated as an inflammatory marker of some PIDs such as 
LRBA deficiency [5].
Th17 cells are also a subset of helper T cells which are responsible for produc-
ing IL-17, a pro-inflammatory cytokine recruiting neutrophils to infection site to 
combat infection [22, 23, 31, 32]. IL-6 expression and STAT3 activation are required 
for the differentiation of Th17 cells from CD4+ T lymphocytes. Therefore in STAT3 
deficiency caused by autosomal dominant loss of function mutations of STAT3 
gene, decreased number of circulating Th17 cells are associated with susceptibil-
ity to Candida infections in STAT3 LOF deficiency which is a type of Autosomal 
Dominant- hyper IgE Syndrome (AD-HIES) [24].
Detection of Tfh and Th17 cell ratios in the peripheral blood of the patients 
with designated PIDs in clinical immunology laboratory by flow cytometry using 
various surface and intracellular markers which are unique to circulating Tfh 
and Th17 cells is important step to understand the inflammatory background of 
the autoimmune manifestations (Figures 2 and 3). See the Section 2.1.1. for the 
 staining protocol.
Below, it was demonstrated Tfh and Th17 gating strategy.
Figure 2. 
Analysis of cTfh cells in a healthy control (top) and a patient with PID (below). In the patient, increased ratio 
of cTfh is observed.
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3. Analysis of surface molecules in PIDs
3.1 Evaluation of molecules which are constitutively expressed on cell surface
In the diagnosis of suspicious patients for PID, flow cytometry is frequently 
applied to detect specific molecules which are expressed on specific subset of 
immune cells in clinical immunology research laboratory [2, 3]. It is used for immu-
nophenotyping as well as in the detection of specific protein expression in cells. In 
the evaluation of constitutively expressed proteins on cell surface, activation with 
specific stimulus is not required. CD40 and CD55 deficiencies are the examples 
which are described in detail in Section 3.1.1. and 3.1.2 for the surface protein 
expression analysis in PIDs.
In the staining of surface proteins, fixation and permeabilization steps are not 
needed. Therefore staining protocol is easier and faster than intracellular staining of 
the proteins which is described in Section 4. Following staining protocol is used to 
detect surface protein expressions in PIDs:
• Add 100 ul of whole blood to flow cytometer tube.
• Add appropriate volume of specific antibodies to detect specific proteins and 
incubate at room temperature and dark conditions for 20–30 min.
• Lyse the erythrocytes using appropriate volume of lysis buffer and incubate for 
10–15 min at room temperature and dark conditions.
• Centrifuge at 500 g for 5 min and discard the supernatant
Figure 3. 
Th17 gating strategy. Increased ratio of Th17 cells expressing IL17A and IL17F are observed in a patient (below) 
compared to healthy control (top).
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• Wash with PBS, centrifuge at 500 g for 5 min and discard the supernatant
• Add 300 ul PBS, vortex and analyze at flow cytometer
3.1.1 CD40 deficiency in hyper IgM syndrome
CD40 is a costimulatory molecule which is expressed on antigen presenting cells 
such as B cells, macrophages and dendritic cells. CD40 interacts with CD40L on T 
cells in GC zones and is activated in the maturation of B cells and isotype switching 
[33, 34]. Similar to CD40L deficiency, CD40 deficiency is investigated for suspi-
cious Hyper IgM syndromes. Decreased or unfunctional CD40 expression on B 
lymphocyte as well as CD40L expression defects on T cells in suspicious patients for 
Hyper IgM syndrome is related to disease occurrence [35, 36]. See the Section 3.1. 
for the staining protocol.
3.1.2 CD55 expression in CHAPLE syndrome
Decay-accelerating factor (DAF) or CD55 is an inhibitor molecule of comple-
ment system and it is related to various diseases and a recently described PID which 
is named as (CD55 deficiency with hyperactivation of complement, angiopathic 
thrombosis, and PLE) CHAPLE syndrome. Because CD55 acts as an inhibitor of 
complement system, low or loss of expressions due to mutations in its encoding 
gene, complement system is more active in patients than healthy individuals [37–39] 
(see the Section 3.1. for the staining protocol).
3.2 Analysis of the expression of induced surface proteins in PIDs
3.2.1 CD40L expression in T lymphocytes in hyper IgM syndrome
CD40L, also known as CD154, is expressed on T cells and responsible for 
the interaction with CD40 which is expressed on antigen presenting cells such 
as B cells. CD40L is a member of TNF-receptor superfamily and its interaction 
with CD40 on B cells is associated with Ig class switching, affinity matura-
tion and GC formation. In most of the patients with CD40L deficiency, loss or 
decreased CD40L protein expression on T cells are associated with increased 
levels of soluble IgM levels and decreased IgG and IgA levels are investigated 
[35, 36]. Expression of CD40L protein on T cell surface is very low and increased 
by activation using Phorbol Myristate Acetate (PMA) and ionomycin inducing 
transcriptional activity of NFAT and AP-1 transcription factors in T cells follow-
ing T cell receptor stimulation. Following 3 hours of activation of PBMCs, CD69 
which is an early activation marker and CD40L expression are detected on T cell 
surface (Figure 4). Staining protocol of CD40L and CD69 on CD3+ CD8- T cells 
are as in below:
• Peripheral blood mononuclear cells (PBMCs) are separated by ficoll density 
gradient protocol from 1 to 2 ml of whole blood in tube with EDTA.
• Wash PBMCs with Phosphate Buffer Saline (PBS) buffer, centrifuge at 300 g 
for 5 min and discard the supernatant and resuspend the cells with serum free 
media.
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• Prepare two flasks for each sample to analyze unstimulated and stimulated 
samples
• Put the appropriate number of cells to culture flask. Add 1 ug/ml PMA and 
500 ng/ml ionomycin to the stimulated culture flask
• Following 3 hours incubation in humidified incubator, wash the cells with PBS 
and centrifuge at 300 g for 5 min and discard the supernatant
• Resuspend the cells with 1 ml PBS and collect 100 ul of cell to a fresh flow 
cytometer tubes
• Add CD3, CD8, CD69 and CD40L antibodies at the appropriate 
concentrations
• Wash with PBS, centrifuge at 500 g for 5 min and discard the supernatant
• Add 300 ul PBS, vortex and analyze at flow cytometer
3.2.2 CD70 expression
CD27/CD70 signaling pathway is significant for the immune response to 
Epstein–Barr virus (EBV) infections. CD27 is expressed on T lymphocytes as well as 
B lymphocytes and whereas its ligand, CD70, is limited to induced T and B lympho-
cytes and dendritic cells. CD27-CD70 signaling is responsible for T cell survival, Treg 
activity, B cell differentiation and proliferation. Due to CD27-CD70 partnership in 
immune response against to EBV, similar clinical characteristics are monitored in 
patients with CD27 and CD70 deficiencies [40–42]. EBV-associated lymphoprolif-
erative disorder, lymphoma, hypogammaglobulinemia and autoimmune manifesta-
tions are generalized clinical symptoms in both deficiencies [41, 42]. Therefore, 
analyzing of CD27 and CD70 proteins in PBMCs using flow cytometry due to its 
rapid and quantitative analysis guide to clinicians as a first step molecular diagnosis 
of patients with these clinical manifestations before sequencing. Figure 5 shows the 
gating strategy for CD70 staining. Staining protocol for CD27 is as in Section 3.1.
Figure 4. 
Gating strategy for CD40L and CD69 expression on CD3+ CD8- T cells in unstimulated and stimulated 
samples from a healthy control (top) and a patient (below).
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CD70 activation and staining protocol is as below:
3.2.2.1  Activation of surface expression of CD70 and staining for flow cytometric 
analysis
• Peripheral blood mononuclear cells (PBMCs) are separated by ficoll  
density gradient protocol from 1 to 2 ml of whole blood in tube with  
EDTA
• Wash PBMCs with Phosphate Buffer Saline (PBS) buffer, centrifuge at 300 g 
for 5 min and discard the supernatant and resuspend the cells with serum free 
media
• Prepare two flasks for each sample to analyze unstimulated and stimulated 
samples
• Put the appropriate number of cells to culture flask and add 2,5 ug/ml phyto-
hemagglutinin (PHA) in the completed culture media
• Incubate the cells in humidified incubator for 72 hours
• After 72 hours add appropriate volume of IL-2 to the cells
• At the day of 8, wash the cells with PBS
• Centrifuge at 500 g for 5 min and discard the supernatant
• Add appropriate volume of CD70 antibody and incubate for 30 min at room 
temperature
• Wash the cells with PBS and Centrifuge at 500 g for 5 min and discard the 
supernatant
• Resuspend the cells with 300 ul PBS and analyze at flow cytometer.
Figure 5. 
A representative image of CD70 expression on CD19+ B lymphocyte in a healthy control and a patient.
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3.2.3 CTLA4 (CD152)
Cytotoxic T lymphocyte Antigen-4 (CTLA4) is an inhibitor ligand of T lymphocytes 
which bind to CD80/CD86 which is found on antigen presenting cells with higher 
affinity than a costimulator molecule CD28 [8–10]. CTLA4 ceases signaling axes in T 
lymphocytes due to its ITIM motifs in the intracytoplasmic domain. Therefore CTLA4 
blocks T cell proliferation and act important function in homeostasis and peripheral tol-
erance. CTLA4 is constitutively expressed on T lymphocytes and it is expressed on cell 
surface only after stimulation via TCR and Ca+/Calcineurin pathway in vitro. In patients 
with autosomal dominant mutation of CTLA4, lymphadenopathy/splenomegaly, hypo-
gammaglobulinemia, cytopenia and organ specific autoimmunity are observed. This 
disease is also called “haploinsufficiency with autoimmune infiltration (CHAI) disease” 
and characterized by unfunctional or loss of CTLA4 expression on T lymphocytes 
[8–10]. Using flow cytometric approach, suspicious patients with CHAI disease may 
be investigated for molecular diagnosis before sequencing. Figure 6 demonstrates the 
gating strategy for CTLA4 expression in healthy control and a patient with PID. Flow 
cytometry protocol for CTLA4 activation and staining are below:
3.2.3.1 Staining protocol of CTLA4 in activated PBMCs
• Peripheral blood mononuclear cells (PBMCs) are separated by ficoll density 
gradient protocol from 1 to 2 ml of whole blood in tube with EDTA
• Wash PBMCs with Phosphate Buffer Saline (PBS) buffer, centrifuge at 300 g for 
5 min and discard the supernatant and resuspend the cells with serum free media
Figure 6. 
A representative image of CTLA4 expression in unstimulated and stimulated PBMC samples obtained from 
in a healthy control (top) and a patient (below). Decreased CTLA4 expression was observed in the patient 
compared to the healthy control.
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• Prepare two flasks for each sample to analyze unstimulated and stimulated 
samples
• Put the appropriate number of cells to culture flask and add 5 ug/ml (PHA) in 
the completed culture media
• Incubate the cells overnight in humidified incubator
• Wash the cells with PBS
• Centrifuge at 500 g for 5 min and discard the supernatant
• Add appropriate volume of CTLA4 antibody and incubate for 30 min at room 
temperature
• Wash the cells with PBS and centrifuge at 500 g for 5 min and discard the 
supernatant
• Resuspend the cells with 300 ul PBS and analyze at flow cytometer
4. Analysis of intracellular molecules in PIDs
4.1 Single protein evaluation in related cell population by flow cytometry
The following protocol is applied to the patients who have suggestive clinical 
history related to LRBA, STK4, DOCK8 and BTK deficiencies before and after 
sequencing to evaluate the alteration of designated protein expressions.
• Peripheral blood mononuclear cells (PBMCs) are separated by ficoll density 
gradient protocol from 1 to 2 ml of whole blood in tube with EDTA
• Wash PBMCs with Phosphate Buffer Saline (PBS) buffer, centrifuge at 300 g 
for 5 min and discard the supernatant and resuspend the cells with PBS
• Add appropriate volume of PBS and add 100 ul cell to flow cytometer tubes
• Add appropriate volume of antibodies related to cells which are interested for 
30 min
• Following incubation wash with PBS, centrifuge at 500 g for 5 min and discard 
the supernatant
• Fix the cells with a fixation buffer for 10–20 min
• Wash with PBS, centrifuge at 500 g for 5 min and discard the supernatant
• Treat with the permeabilization buffer for 10–30 min
• Wash with PBS, centrifuge at 500 g for 5 min and discard the supernatant
• Incubate with related antibody for 30 min
11
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• Wash the cells with PBS and centrifuge at 500 g for 5 min and discard the 
supernatant
• Resuspend the cells with 300 ul PBS and analyze at flow cytometer
4.1.1 LRBA deficiency
(Lipopolysaccharide responsive beige-like anchor protein) LRBA plays impor-
tant roles in vesicle trafficking and receptor recycling. LRBA is responsible for 
CTLA4 trafficking from vesicular compartments to the cell membrane. In patients 
with LRBA mutations, an autosomal recessive form of combined immunodeficiency 
arises and this deficiency is associated with hypogammaglobulinemia, recurrent 
respiratory infections, multiple autoimmune manifestations and frequently suscep-
tibility to inflammatory bowel disease and malignity in some cases [4, 6, 7, 43–45]. 
See the Section 4.1. for the staining protocol. Figure 7 shows a representative image 
of LRBA expression in LRBA deficient patient and a healthy control.
4.1.2 STK4 (MST1) deficiency
STK4 (serine–threonine protein kinase 4), also known as MST1 (Macrophage 
Stimulating 1), was first found in Drosophila as a member of the Hippo pathway, 
which regulates proliferation and cell survival. Human STK4 is principally discov-
ered as a constitutively expressed kinase, structurally homologous to the Drosophila 
Hippo, and plays roles in vital biologic processes such as morphogenesis, prolifera-
tion, apoptosis, and stress response [46–49]. STK4 deficiency was first defined 
in 2012 by 3 separate groups as causing a novel autosomal recessive CID, which is 
characterized by a profoundly decreased level of CD4+ T cells with the concomitant 
tendency to recurrent viral and bacterial infections and mucocutaneous candidiasis 
[46, 49]. Mutations in STK4 gene cause the lack of protein expression or severely 
reduced level of protein expression [50] (Figure 8). See the Section 4.1. for the 
staining protocol.
Figure 7. 
A representative image of LRBA expression in a negative control (NC 0r isotype control), positive or healthy 
control (PC) and a patient (P). Decreased LRBA expression was observed in the patient compared the PC.
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4.1.3 DOCK8 deficiency
DOCK8 is a member of DOCK-C family and is responsible for activation of 
GTPases such as CDC42 and RAC. Therefore it transmit the signals from the 
membrane to intracellular compartment of cells and involves the cytoskeletal rear-
rangement of the cells. Decreased expression or total loss of DOCK8 protein due to 
bi-allelic mutations of DOCK8 gene cause Autosomal-Recessive Hyper-IgE Syndrome 
(AR-HIES) which is associated with eosinophilia and elevated IgE levels in the 
effected patients [51–53] (Figure 9). See the Section 4.1. for the staining protocol.
4.1.4 BTK deficiency in XLA
BTK is a member of Tec family of non-receptor tyrosine kinases and plays a role 
in the transmission of the signals from the membrane into the cell. BTK localizes 
Figure 8. 
A representative image of STK4 expression in isotype control (blue), healthy control (green) and the patient 
(red). Decreased STK4 expression was observed in the patient compared to the healthy control [50].
Figure 9. 
A representative image of DOCK8 expression in healthy control (top) and the patient (below). Decreased 
DOCK8 expression was observed in the patient compared to the healthy control.
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next to BCR in B cells, therefore it is important for B cell development. In mutations 
of BTK which is present on X-chromosome cause X-linked agammaglobulinemia 
in patients who suffered from recurrent bacterial infections due to low or nearly 
undetectable immunoglobulins and B lymphocytes [54]. Lymphocyte phenotyping 
is frequently used to diagnose the diseases in patients with suspicious clinical find-
ings and BTK expression is analyzed for molecular diagnosis underlying the XLA. 
Figure 10 demonstrates the BTK expression in a patients’ and a healthy controls’ 
samples. See the Section 4.1. for the staining protocol.
4.2 Pathway characterization in PIDs
4.2.1 PI3K pathway characterization
Activated phosphoinositide-3 kinase-δ syndrome (APDS) also known as p110δ-
activating mutation causing senescent T cells, lymphadenopathy and immunode-
ficiency (PASLI) occurs in patients with combined immunodeficiency due to gain 
of function mutations of phosphoinositide 3-kinase (PI3K) genes PIK3CD and 
Figure 10. 
BTK expression in isotype control (top) healthy control (middle) and the patient (below). BTK expression was 
lower in the patient than the healthy control.
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PIK3R1 [14, 16–18]. Although clinical manifestations are heterogenous among the 
patients, recurrent and persistent infections with herpes family viruses, lympho-
proliferation, immune cytopenia are observed in the majority of the patients. 
Investigating the pathway in patients with suggestive to APDS or PASLI, PI3K 
pathway analysis, downstream kinase phosphorylations with or without stimula-
tion with specific receptors such as TCR or BCR are investigated by flow cytometry 
[16]. In the latter section, staining protocol of the PIK3δ, p-Akt and p-mTOR 
are summarized. Figure 11 shows a representative image of p-Akt and p-mTOR 
expression in a patient with PIK3δ GOF deficiency and a healthy control sample.
4.2.1.1 PIK3δ and downstream pathway activation and staining protocol
• Peripheral blood mononuclear cells (PBMCs) are separated by ficoll density 
gradient protocol from 1 to 2 ml of whole blood in tube with EDTA
• Wash PBMCs with Phosphate Buffer Saline (PBS) buffer, centrifuge at 300 g 
for 5 min and discard the supernatant and resuspend the cells with serum free 
media
• Prepare two flasks for each sample to analyze unstimulated and stimulated 
samples
• Put the appropriate number of cells to culture flask and add an appropriate 
receptor activating agent to induce the pathway and incubate in humidified 
incubator in suggested time depend on the agent used in the activation
• Centrifuge at 500 g for 5 min and discard the supernatant
Figure 11. 
Ratio of cells expressing p-Akt and p-mTOR in a patient with PIK3δ GOF deficiency and a healthy control 
following pathway stimulation as described in section 4.2.1.1.
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• Add appropriate volume of PIK3δ, p-Akt and p-mTOR antibodies and incubate 
for 30 min at room temperature
• Wash the cells with PBS and centrifuge at 500 g for 5 min and discard the 
supernatant
• Resuspend the cells with 300 ul PBS and analyze at flow cytometer
5. Analysis of cellular functions of immune cells
5.1 Cell proliferation
Severe combined immunodeficiencies (CIDs) including T-B + NK-, T-B-NK+, 
T-B-NK- and T-B + NK+ and/or isolated T cell deficiencies are severe forms of PIDs 
due to important roles of T lymphocytes to combat directly or indirectly protein and 
viral antigens [55]. T lymphocytes have specific subsets to achieve their superior 
roles on specific antigenic determinant. Their deficiencies due to specific molecular 
defects affect their activation, receptor editing, functions and proliferative capacity 
cause critically ill disease phenotype. They need to re-regulate their receptors and 
proliferate to expand agent-specific clones such an army to combat during vari-
ous specific-infections. Therefore detecting cell proliferation is significant for the 
diagnosis and/or the course of the disease. Non-radioactive cell tracking dyes such 
as CFSE (carboxyfluorescein succinimidyl ester) has been started to use for the 
assessment of cell proliferation in flow cytometry. CFSE is a non-fluorescent dye 
and becomes permeable through its two acetate groups and passing through the cell 
membrane. After entering the cells, following the separation of acetate groups via 
esterases, it becomes fluorescent and its permeability is decreased. Succinimidyl 
group of CFSE reacts with amino groups of mostly from lysine residues of intracel-
lular molecules such as cytoskeletal proteins and forms stable covalent bonds. In 
Figure 12. 
Comparison of CD3+ T lymphocyte proliferation between a patient with SCID and a healthy control 
individual. Normal proliferation in the healthy control sample (top) and loss of CD3+ T lymphocyte 
proliferation in the patient with SCID (below).
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each cell division its fluorescent density is decreased and this decrease in cells is 
evaluated in flow cytometry [56–58]. Severely affected lymphocyte proliferation in 
a patient with severe combined immunodeficiency is shown in Figure 12. See the 
CFSE cell staining protocol in Section 5.1.1.
5.1.1 CFSE staining protocol
• Peripheral blood mononuclear cells (PBMCs) are separated by ficoll density 
gradient protocol from 1 to 2 ml of whole blood in tube with EDTA
• Wash PBMCs with Phosphate Buffer Saline (PBS) buffer, centrifuge at 300 g 
for 5 min and discard the supernatant and resuspend the cells with serum free 
media
• Prepare two flasks to analyze the proliferation in unstimulated and stimulated 
cells
• Put the appropriate number of cells to culture flask and label them with the 
appropriate concentration of CFSE for 5–10 minutes in dark conditions
• Centrifuge at 500 g for 5 min and discard the supernatant for two times
• Add appropriate volume of T cell activator such as PHA (Phorbol Myristate 
Acetate) to stimulate the cells
• Incubate cells for 72–96 hours in humidified conditions
• Wash the cells with PBS and centrifuge at 500 g for 5 min and discard the 
supernatant
• Incubate with appropriate volume of anti-CD3 antibody
• Wash the cells with PBS and centrifuge at 500 g for 5 min and discard the 
supernatant
• Resuspend the cells with 300 ul PBS and analyze at flow cytometer.
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